PURPOSE: Approaches for the synthesis of biomaterials to facilitate the delivery of "biologics" is a major area of research in cancer therapy. Here we designed and characterized a hyaluronic acid (HA) based self-assembling nanoparticles that can target CD44 receptors overexpressed on multidrug resistance (MDR) ovarian cancer. The nanoparticle system is composed of HA-poly(ethyleneimine)/HA-poly(ethylene glycol) (HA-PEI/HA-PEG) designed to deliver MDR1 siRNA for the treatment of MDR in an ovarian cancer model. METHODS: HA-PEI/HA-PEG nanoparticles were synthesized and characterized, then the cellular uptake and knockdown efficiency of HA-PEI/HA-PEG/MDR1 siRNA nanoparticles was further determined. A human xenograft MDR ovarian cancer model was established to evaluate the effects of the combination of HA-PEI/HA-PEG/MDR1 siRNA nanoparticles and paclitaxel on MDR tumor growth. RESULTS: Our results demonstrated that HA-PEI/HA-PEG nanoparticles successfully targeted CD44 and delivered MDR1 siRNA into OVCAR8TR (established paclitaxel resistant) tumors. Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel. HA-PEI/HA-PEG/MDR1 siRNA nanoparticle therapy followed by paclitaxel treatment inhibited tumor growth in MDR ovarian cancer mouse models. CONCLUSIONS: These findings suggest that this CD44 targeted HA-PEI/HA-PEG nanoparticle platform may be a clinicaly relevant gene delivery system for systemic siRNA-based anticancer therapeutics for the treatment of MDR cancers.
PURPOSE: Approaches for the synthesis of biomaterials to facilitate the delivery of "biologics" is a major area of research in cancer therapy. Here we designed and characterized a hyaluronic acid (HA) based self-assembling nanoparticles that can target CD44 receptors overexpressed on multidrug resistance (MDR) ovarian cancer. The nanoparticle system is composed of HA-poly(ethyleneimine)/HA-poly(ethylene glycol) (HA-PEI/HA-PEG) designed to deliver MDR1 siRNA for the treatment of MDR in an ovarian cancer model. METHODS:HA-PEI/HA-PEG nanoparticles were synthesized and characterized, then the cellular uptake and knockdown efficiency of HA-PEI/HA-PEG/MDR1 siRNA nanoparticles was further determined. A humanxenograft MDR ovarian cancer model was established to evaluate the effects of the combination of HA-PEI/HA-PEG/MDR1 siRNA nanoparticles and paclitaxel on MDRtumor growth. RESULTS: Our results demonstrated that HA-PEI/HA-PEG nanoparticles successfully targeted CD44 and delivered MDR1 siRNA into OVCAR8TR (established paclitaxel resistant) tumors. Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel. HA-PEI/HA-PEG/MDR1 siRNA nanoparticle therapy followed by paclitaxel treatment inhibited tumor growth in MDR ovarian cancermouse models. CONCLUSIONS: These findings suggest that this CD44 targeted HA-PEI/HA-PEG nanoparticle platform may be a clinicaly relevant gene delivery system for systemic siRNA-based anticancer therapeutics for the treatment of MDR cancers.
Authors: Ki Young Choi; Hong Yeol Yoon; Jong-Ho Kim; Sang Mun Bae; Rang-Woon Park; Young Mo Kang; In-San Kim; Ick Chan Kwon; Kuiwon Choi; Seo Young Jeong; Kwangmeyung Kim; Jae Hyung Park Journal: ACS Nano Date: 2011-10-11 Impact factor: 15.881
Authors: Vatsal Shah; Oleh Taratula; Olga B Garbuzenko; Olena R Taratula; Lorna Rodriguez-Rodriguez; Tamara Minko Journal: Clin Cancer Res Date: 2013-09-13 Impact factor: 12.531
Authors: Evelina Miele; Gian Paolo Spinelli; Ermanno Miele; Enzo Di Fabrizio; Elisabetta Ferretti; Silverio Tomao; Alberto Gulino Journal: Int J Nanomedicine Date: 2012-07-20
Authors: Jennifer M Wickens; Hashem O Alsaab; Prashant Kesharwani; Ketki Bhise; Mohd Cairul Iqbal Mohd Amin; Rakesh Kumar Tekade; Umesh Gupta; Arun K Iyer Journal: Drug Discov Today Date: 2016-12-23 Impact factor: 7.851
Authors: Sean W Harshman; Alessandro Canella; Paul D Ciarlariello; Kitty Agarwal; Owen E Branson; Alberto Rocci; Hector Cordero; Mitch A Phelps; Erinn M Hade; Jason A Dubovsky; Antonio Palumbo; Ashley Rosko; John C Byrd; Craig C Hofmeister; Don M Benson; Michael E Paulaitis; Michael A Freitas; Flavia Pichiorri Journal: J Proteomics Date: 2016-01-13 Impact factor: 4.044